Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

apital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's therapeutic focus is oncology, but is also developing therapeutic products for inflammation, metabolic, and infectious diseases, as well as for the treatment of chronic pain. Sorrento's proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutics. In addition, Sorrento is developing proprietary Antibody Drug Conjugates as well as Antibody formulated Drug Conjugates combining its G-MAB® antibodies with anti-tumor agents.

More information is available at www.sorrentotherapeutics.com.

Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sor
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014  Encision Inc. (OTCQB:ECIA), a medical device company ... burns in minimally invasive surgery, today announced financial results ... 2014. The Company posted quarterly net revenue ... $414 thousand, or $(0.04) per share. These results compare ... loss of $50 thousand, or $(0.01) per share, in ...
(Date:10/31/2014)... , Oct. 31, 2014 /CNW Telbec/ - Ergoresearch ... its strategic plan, for accelerated growth in terms of ... and revenues reached $17,862,341. Net income amounted to $1,230,153. ... for the first time in the Company,s history. ... Company joined the forces of its subsidiaries, merging in ...
(Date:10/31/2014)... Research and ... the  "Process Validation in the US and EU ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to include:  ... to Process Validation for Pharmaceutical and Biopharmaceutical Products ... Process Validation Guidance EU Process Validation ...
Breaking Medicine Technology:Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... mass index (BMI) should be taken into account when assessing ... Cancer Treatment Centers of America (CTCA), ... of vitamin D compared to non-obese patients. , , ... , The association between vitamin D and obesity remains unsettled ...
... Calif., June 12 Masimo (Nasdaq: MASI ... and Low-Perfusion pulse oximetry, announced today that three new ... Masimo PVI as a noninvasive and continuous measure of ... at the European Society of Anaesthesiology (ESA) Annual Congress ...
Cached Medicine Technology:Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Sleep apnea may make it ... you parked your car or left your house keys, a ... sleep apnea showed that this ability -- called spatial memory ... (REM) sleep, even when other stages of sleep weren,t affected. ... dreams typically occur. "We,ve shown for the first time ...
(Date:10/31/2014)... lab device to give cancer researchers an unprecedented microscopic ... spread through the body, causing more than 90 percent ... tumor cells travel, the device could uncover new ways ... the university,s Whiting School of Engineering and its Institute ... new system recently in the journal Cancer Research ...
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
(Date:10/31/2014)... Phoenix, AZ (PRWEB) October 31, 2014 ... off all dental treatments for November. Whether patients simply need ... there is no better time than now to get that ... but many patients put off routine and even essential treatments ... patients can enjoy substantial savings on any treatments offered by ...
(Date:10/31/2014)... 31, 2014 Adults 65 and ... their Medicare coverage during the current open enrollment ... library for step-by-step guidance, the company announced today. ... on choosing the correct Medicare Advantage plan, understanding ... open enrollment. , “With just one month remaining ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
... Indian state of Tamil Nadu has decided to transfer the ... for the anti-cancer drug Glivec to the Intellectual Property Appellate ... setback to the pharma multinational. ,For it cannot ... Appellate Board’s ruling too can be challenged it in the ...
... United States, are now spreading their wings with distant shores ... Hopkins clinic will be set up at Tokyo, Japan. ... Japan’s growing discontent with the national health-care system. Accordingly, around ... by caring for an aging population. This has even got ...
... the ultimate cocktail dress: it's made from red wine, smells like ... spilled on it.// ,The fabric is actually the papery ... finds its way in. ,To form the dress, the wet, ... partially dry out. Deflate the doll, and the finished dress comes ...
... towards a successful womb transplant. // ,Four sheep ... reconnected, Swedish scientists say. ,Professor Mats Brannstrom ... - where the same womb is removed and reconnected. ... in the study developed fatal complications and hence it would ...
... circuitry using textile's threads to monitor the medical condition ... ,This may sound complex, but it is a ... ,In 1996, researchers at Georgia Institute of Technology ... with sensors capable of monitoring a patient's heartbeat, temperature ...
... Center for Devices and Radiological Health of the Food and ... Danek to market INFUSE? Bone Graft for use in dental ... FDA as a replacement for autograft in spinal fusion procedures ... ,"FDA approval of INFUSE marks a major step forward ...
Cached Medicine News:Health News:Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board 2Health News:Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board 3Health News:John Hopkins Hospitals- Now at Tokyo 2Health News:Womb Transplant Pregnancy Success 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: